This Eczema Drug Just Got an FDA-Approved Upgrade
My AccountFIND A DOCTORFaceAdult AcneAnti-AgingAntioxidantsCelebrityChronic Skin ConditionsEyeHydrationHyperpigmentationMakeupMale Skin CarePeelsPre-Event PrepRetinoidsSensitive SkinSkin CareSkin HealthSmileSun CareTreatmentsAnti-WrinkleFillersMicroneedlingNeurotoxinsPost-Procedure Skin CareRegenerative AestheticsBodyBody SculptingBreastsButtsCelluliteFind a DoctorHair RemovalHands + NailsLegsPregnancyHairBond RepairCelebrity HairDry HairFrizzy HairGray HairHair ColorHair GrowthHair RepairScalp HealthTips + TutorialsAwardsNB100 Awards16th Annual Beauty Awards2025 NewBeauty Readers’ Choice AwardsShoppingBeautyReportGift GuidesNewBeauty StorefrontProduct ReviewsWellnessFitnessGLP-1sHealthMenopauseAbout UsTESTTUBEFaceView All FaceAdult AcneAnti-AgingAntioxidantsCelebrityChronic Skin ConditionsEyeHydrationHyperpigmentationMakeupMale Skin CarePeelsPre-Event PrepRetinoidsSensitive SkinSkin CareSkin HealthSmileSun CareTreatmentsView All TreatmentsAnti-WrinkleFillersMicroneedlingNeurotoxinsPost-Procedure Skin CareRegenerative AestheticsBodyView All BodyBody SculptingBreastsButtsCelluliteFind a DoctorHair RemovalHands + NailsLegsPregnancyHairView All HairBond RepairCelebrity HairDry HairFrizzy HairGray HairHair ColorHair GrowthHair RepairScalp HealthTips + TutorialsAwardsView All AwardsNB100 Awards16th Annual Beauty Awards2025 NewBeauty Readers’ Choice AwardsShoppingView All ShoppingBeautyReportGift GuidesNewBeauty StorefrontProduct ReviewsWellnessView All WellnessFitnessGLP-1sHealthMenopauseAbout UsLoading…FIND A DOCTORTESTTUBE Advertisement Home›Skin Care›Chronic Skin Conditions This Eczema Drug Just Got an FDA-Approved Upgrade Fewer injections, same long-term control. Living with moderate to severe eczema is hard enough, but a new US Food and Drug Administration (FDA) decision just made managing it a little easier. The FDA has approved an every-8-week dosing schedule for EBGLYSS (lebrikizumab), a biologic medication used to treat adults and adolescents 12 and older with moderate to severe eczema or atopic dermatitis (AD). As reported by Dermatology Times, the approval expands dosing options for the medication, which was previously approved with a once-monthly maintenance schedule. With the new regimen, patients who qualify may keep their eczema under control with as few as six injections per year following the initial treatment period.